- Home
- UMAC vs AVLN Comparison
UMAC vs AVLN Comparison
Compare UMAC & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UMAC | AVLN |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2023 | 2026 |
Fundamental Metrics
Financial Performance| Metric | UMAC | AVLN |
|---|---|---|
| Price | $24.03 | $32.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 181.8K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.73 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $11,199,217.00 | N/A |
| Revenue This Year | $115.39 | N/A |
| Revenue Next Year | $101.44 | N/A |
| P/E Ratio | $404.00 | ★ N/A |
| Revenue Growth | ★ 101.23 | N/A |
| 52 Week Low | $7.25 | $24.90 |
| 52 Week High | $34.93 | $40.17 |
Technical Indicators
Market Signals| Indicator | UMAC | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 38.17 |
| Support Level | $22.12 | $25.86 |
| Resistance Level | $26.07 | $33.32 |
| Average True Range (ATR) | 1.55 | 2.25 |
| MACD | -0.08 | -0.66 |
| Stochastic Oscillator | 42.09 | 6.08 |
Price Performance
Historical ComparisonAbout UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in manufactures and sells drone components and drones across a diversified brand portfolio through business-to-business (B2B) sales and a curated retail channel.
About AVLN Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.